132 related articles for article (PubMed ID: 17903082)
1. Progression to AIDS and death and response to HAART in men and women from a multicenter hospital-based cohort.
Perez-Hoyos S; Rodríguez-Arenas MA; García de la Hera M; Iribarren JA; Moreno S; Viciana P; Peña A; Gómez Sirvent JL; Saumoy M; Lacruz J; Padilla S; Oteo JA; Asencio R; Del Amo J;
J Womens Health (Larchmt); 2007 Sep; 16(7):1052-61. PubMed ID: 17903082
[TBL] [Abstract][Full Text] [Related]
2. Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain.
Rodríguez-Arenas MA; Jarrín I; del Amo J; Iribarren JA; Moreno S; Viciana P; Peña A; Sirvent JL; Vidal F; Lacruz J; Gutierrez F; Oteo JA; Asencio R; Castilla J; Hoyos SP;
AIDS Res Hum Retroviruses; 2006 Aug; 22(8):715-23. PubMed ID: 16910826
[TBL] [Abstract][Full Text] [Related]
3. Short communication. Association of the CCR5delta32 mutation with clinical response and >5-year survival following initiation of first triple antiretroviral regimen.
Brumme ZL; Henrick BM; Brumme CJ; Hogg RS; Montaner JS; Harrigan PR
Antivir Ther; 2005; 10(7):849-53. PubMed ID: 16312181
[TBL] [Abstract][Full Text] [Related]
4. Gender differences in progression to AIDS and death from HIV seroconversion in a cohort of injecting drug users from 1986 to 2001.
García de la Hera M; Ferreros I; del Amo J; García de Olalla P; Pérez Hoyos S; Muga R; del Romero J; Guerrero R; Hernández-Aguado I;
J Epidemiol Community Health; 2004 Nov; 58(11):944-50. PubMed ID: 15483312
[TBL] [Abstract][Full Text] [Related]
5. Treatment outcome of HAART-treated patients in a resource-limited setting: the Belgrade Cohort Study.
Jevtović D; Dragovic G; Salemović D; Ranin J; Kušić J; Marinković J; Djurković-Djaković O
Biomed Pharmacother; 2014 Apr; 68(3):391-5. PubMed ID: 24486106
[TBL] [Abstract][Full Text] [Related]
6. Late initiation of HAART among HIV-infected patients in Spain is frequent and related to a higher rate of virological failure but not to immigrant status.
Pérez-Molina JA; Suárez-Lozano I; Del Arco A; Teira R; Bachiller P; Pedrol E; Martínez-Alfaro E; Domingo P; Mariño A; Ribera E; Antela A; de Otero J; Navarro V; González-García J;
HIV Clin Trials; 2011; 12(1):1-8. PubMed ID: 21388936
[TBL] [Abstract][Full Text] [Related]
7. Mortality and its predictors among highly active antiretroviral therapy naive hiv-infected individuals: data from prospective cohort study in Ukraine.
Zhyvytsia D
Georgian Med News; 2014; (232-233):69-74. PubMed ID: 25214276
[TBL] [Abstract][Full Text] [Related]
8. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
[TBL] [Abstract][Full Text] [Related]
9. Epidemiological and clinical features, response to HAART, and survival in HIV-infected patients diagnosed at the age of 50 or more.
Nogueras M; Navarro G; Antón E; Sala M; Cervantes M; Amengual M; Segura F
BMC Infect Dis; 2006 Nov; 6():159. PubMed ID: 17087819
[TBL] [Abstract][Full Text] [Related]
10. Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain).
Jaén A; Esteve A; Miró JM; Tural C; Montoliu A; Ferrer E; Riera M; Segura F; Force L; Sued O; Vilaró J; Garcia I; Masabeu A; Altès J; Coltet B; Podzamczer D; Murillas J; Navarro G; Gatell JM; Casabona J;
J Acquir Immune Defic Syndr; 2008 Feb; 47(2):212-20. PubMed ID: 18297762
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort.
Gutierrez F; Padilla S; Masiá M; Iribarren JA; Moreno S; Viciana P; Muñoz L; Gómez Sirvent JL; Vidal F; López-Aldeguer J; Blanco JR; Leal M; Rodríguez-Arenas MA; Perez Hoyos S;
PLoS One; 2006 Dec; 1(1):e89. PubMed ID: 17183720
[TBL] [Abstract][Full Text] [Related]
12. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
[TBL] [Abstract][Full Text] [Related]
13. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.
Tai JH; Udoji MA; Barkanic G; Byrne DW; Rebeiro PF; Byram BR; Kheshti A; Carter JD; Graves CR; Raffanti SP; Sterling TR
J Infect Dis; 2007 Oct; 196(7):1044-52. PubMed ID: 17763327
[TBL] [Abstract][Full Text] [Related]
14. Impact of highly active antiretroviral therapy (HAART) on AIDS and death in a cohort of vertically HIV type 1-infected children: 1980-2006.
Palladino C; Bellón JM; Jarrín I; Gurbindo MD; De José MI; Ramos JT; González-Iome MI; Mellado MJ; Beceiro J; Del Amo J; Muñoz-Fernández MA
AIDS Res Hum Retroviruses; 2009 Nov; 25(11):1091-7. PubMed ID: 19895191
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
[TBL] [Abstract][Full Text] [Related]
16. Predictors of early mortality in a cohort of HIV-infected children receiving high active antiretroviral treatment in public hospitals in Ethiopia.
Ebissa G; Deyessa N; Biadgilign S
AIDS Care; 2015; 27(6):723-30. PubMed ID: 25599414
[TBL] [Abstract][Full Text] [Related]
17. Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care?
Mocroft A; Gill MJ; Davidson W; Phillips AN
J Acquir Immune Defic Syndr; 2000 Aug; 24(5):475-82. PubMed ID: 11035619
[TBL] [Abstract][Full Text] [Related]
18. Relevant gender differences in epidemiological profile, exposure to first antiretroviral regimen and survival in the Spanish AIDS Research Network Cohort.
Pérez-Elías MJ; Muriel A; Moreno A; Martinez-Colubi M; Iribarren JA; Masiá M; Blanco JR; Palacios R; Del Romero J; Pérez DG; Hernando V;
Antivir Ther; 2014; 19(4):375-85. PubMed ID: 24304821
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus coinfection and HIV load, CD4+ cell percentage, and clinical progression to AIDS or death among HIV-infected women: Women and Infants Transmission Study.
Hershow RC; O'Driscoll PT; Handelsman E; Pitt J; Hillyer G; Serchuck L; Lu M; Chen KT; Yawetz S; Pacheco S; Davenny K; Adeniyi-Jones S; Thomas DL
Clin Infect Dis; 2005 Mar; 40(6):859-67. PubMed ID: 15736020
[TBL] [Abstract][Full Text] [Related]
20. Response to HAART in treatment-naive HIV-infected patients with a prior diagnosis of tuberculosis or other opportunistic infections.
Dronda F; Sobrino P; Hernández-Novoa B; Caro-Murillo AM; Montero M; Iribarren JA; Sanz J; Del Mar Alonso M; Labarga P; Bernal E; Moreno S;
Curr HIV Res; 2011 Jun; 9(4):229-36. PubMed ID: 21631429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
